U.S. markets close in 1 hour 4 minutes
  • S&P 500

    4,537.61
    +1.42 (+0.03%)
     
  • Dow 30

    35,511.18
    -98.16 (-0.28%)
     
  • Nasdaq

    15,177.42
    +55.74 (+0.37%)
     
  • Russell 2000

    2,287.17
    -2.59 (-0.11%)
     
  • Crude Oil

    82.54
    -0.88 (-1.05%)
     
  • Gold

    1,781.00
    -3.90 (-0.22%)
     
  • Silver

    24.14
    -0.31 (-1.27%)
     
  • EUR/USD

    1.1628
    -0.0024 (-0.21%)
     
  • 10-Yr Bond

    1.6790
    +0.0430 (+2.63%)
     
  • GBP/USD

    1.3785
    -0.0040 (-0.29%)
     
  • USD/JPY

    113.8700
    -0.4590 (-0.40%)
     
  • BTC-USD

    62,718.29
    -3,774.84 (-5.68%)
     
  • CMC Crypto 200

    1,485.61
    -49.04 (-3.20%)
     
  • FTSE 100

    7,190.30
    -32.80 (-0.45%)
     
  • Nikkei 225

    28,708.58
    -546.97 (-1.87%)
     

Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass. & MONTREAL, September 02, 2021--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced that members of its senior management team will participate in a fireside chat at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference on Thursday, September 9 at 2:45 p.m. Eastern Time.

A live webcast of the fireside chat can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 30 days.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes its lead product candidate RP-3500, a potential leading ATR inhibitor currently in Phase 1/2 clinical development, its second clinical candidate, RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development, a Polθ inhibitor program, as well as eight other early-stage, pre-clinical programs. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210902005249/en/

Contacts

Repare Contact:

Steve Forte
Chief Financial Officer
Repare Therapeutics Inc.
info@reparerx.com

Investors:

Kimberly Minarovich
Argot Partners
repare@argotpartners.com

Media:
David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902